Pandemic 1918 Influenza Virus Does Not Cause Lethal Infection in Rhesus or Cynomolgus Macaques.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
24 08 2022
Historique:
pubmed: 5 8 2022
medline: 27 8 2022
entrez: 4 8 2022
Statut: ppublish

Résumé

The 1918 H1N1 influenza pandemic was among the most severe in history, taking the lives of approximately 50 million people worldwide, and novel prophylactic vaccines are urgently needed to prevent another pandemic. Given that macaques are physiologically relevant preclinical models of human immunology that have advanced the clinical treatment of infectious diseases, a lethal pandemic influenza challenge model would provide a stringent platform for testing new influenza vaccine concepts. To this end, we infected rhesus macaques and Mauritian cynomolgus macaques with highly pathogenic 1918 H1N1 influenza virus and assessed pathogenesis and disease severity. Despite infection with a high dose of 1918 influenza delivered via multiple routes, rhesus macaques demonstrated minimal signs of disease, with only intermittent viral shedding. Cynomolgus macaques infected via intrabronchial instillation demonstrated mild symptoms, with disease severity depending on the infection dose. Cynomolgus macaques infected with a high dose of 1918 influenza delivered via multiple routes experienced moderate disease characterized by consistent viral shedding, pulmonary infiltrates, and elevated inflammatory cytokine levels. However, 1918 influenza was uniformly nonlethal in these two species, demonstrating that this isolate is insufficiently pathogenic in rhesus and Mauritian cynomolgus macaques to support testing novel prophylactic influenza approaches where protection from severe disease combined with a lethal outcome is desired as a highly stringent indication of vaccine efficacy.

Identifiants

pubmed: 35924920
doi: 10.1128/jvi.00728-22
pmc: PMC9400491
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0072822

Subventions

Organisme : NIH HHS
ID : P51 OD011092
Pays : United States

Références

mBio. 2019 Oct 22;10(5):
pubmed: 31641086
PLoS One. 2015 May 06;10(5):e0126132
pubmed: 25946071
J Hered. 2009 Mar-Apr;100(2):158-69
pubmed: 18974398
J Med Primatol. 2013 Jun;42(3):120-31
pubmed: 23480663
J Med Virol. 2001 Jul;64(3):262-8
pubmed: 11424113
J Immunol. 2017 Feb 15;198(4):1616-1626
pubmed: 28062701
Exp Gerontol. 2010 Sep;45(9):655-61
pubmed: 20558288
Biomed Res Int. 2021 Oct 13;2021:9533044
pubmed: 34692846
Science. 2012 Jun 22;336(6088):1534-41
pubmed: 22723413
J Infect Dis. 1999 Sep;180(3):586-93
pubmed: 10438343
Viruses. 2020 Jan 05;12(1):
pubmed: 31948040
Virology. 2010 Nov 25;407(2):178-84
pubmed: 20822788
Nature. 2007 Jan 18;445(7125):319-23
pubmed: 17230189
Vaccine. 2001 Oct 12;20(1-2):158-63
pubmed: 11567760
Age (Dordr). 2012 Oct;34(5):1169-77
pubmed: 22231440
PLoS Pathog. 2011 Nov;7(11):e1002381
pubmed: 22102819
Am J Primatol. 2013 Feb;75(2):135-44
pubmed: 23165690
J Clin Invest. 1998 Feb 1;101(3):643-9
pubmed: 9449698
Nature. 2012 May 02;486(7403):420-8
pubmed: 22722205
Comp Med. 2010 Oct;60(5):389-95
pubmed: 21262125
Vet Rec. 1985 Apr 20;116(16):431-6
pubmed: 3923690
Vet Pathol. 2003 May;40(3):304-10
pubmed: 12724572
J Virol. 2001 Jul;75(14):6687-91
pubmed: 11413336
Nature. 1997 Oct 9;389(6651):554
pubmed: 9335492
J Infect Dis. 2018 Mar 28;217(8):1237-1246
pubmed: 29329410
J Infect Dis. 1999 Jul;180(1):10-4
pubmed: 10353855
Science. 2005 Oct 7;310(5745):77-80
pubmed: 16210530
J Infect Dis. 2020 Sep 1;222(7):1155-1164
pubmed: 32433769

Auteurs

Mable Chan (M)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Meenakshi Tiwary (M)

Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, USA.
Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, USA.

Helen L Wu (HL)

Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, USA.
Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, USA.

Nikesh Tailor (N)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Robert Vendramelli (R)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Jonathan Audet (J)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Bryce M Warner (BM)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Kevin Tierney (K)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Alix Albietz (A)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Thang Truong (T)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Kaylie Doan (K)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Alexander Bello (A)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Marnie Willman (M)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.

Bryan D Griffin (BD)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.
Vaccine Safety Surveillance, Immunization Branch, Public Health Agency of Canadagrid.415368.d, Ottawa, Ontario, Canada.

Patrick W Hanley (PW)

Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.

Jamie Lovaglio (J)

Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseasesgrid.419681.3, National Institutes of Health, Hamilton, Montana, USA.

David Safronetz (D)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.

Jim Strong (J)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.

Jonah B Sacha (JB)

Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, USA.
Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon, USA.

Darwyn Kobasa (D)

Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canadagrid.415368.d, Winnipeg, Manitoba, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH